lovastatin has been researched along with puromycin aminonucleoside in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guijarro, C; Kasiske, BL; Keane, WF; Kim, Y; Massy, ZA; O'Donnell, MP; Park, YS | 1 |
| Drukker, A; Eddy, AA | 1 |
2 other study(ies) available for lovastatin and puromycin aminonucleoside
| Article | Year |
|---|---|
Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats.
Topics: Animals; Chemokine CCL2; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Glomerulus; Lovastatin; Macrophages; Male; Nephrosis; Polymerase Chain Reaction; Puromycin Aminonucleoside; Rats; Rats, Sprague-Dawley; RNA, Messenger | 1998 |
Failure of antioxidant therapy to attenuate interstitial disease in rats with reversible nephrotic syndrome.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Cholesterol; Collagen; Female; Fibronectins; Fibrosis; Kidney; Lipid Peroxides; Lipoproteins, LDL; Liver; Lovastatin; Macrophages; Microscopy, Fluorescence; Nephrotic Syndrome; Organ Size; Probucol; Proteinuria; Puromycin Aminonucleoside; Rats; Rats, Sprague-Dawley; Time Factors; Transforming Growth Factor beta; Treatment Failure; Vitamin E | 1998 |